Safety and immunogenicity of a gag-pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects

The safety and immunogenicity of a candidate HIV DNA vaccine administered by using a needle-free device is evaluated. The results have shown that the HIV DNA vaccine is safe and well tolerated and it has led to the development of a 4-plasmid multiclade HIV DNA Vaccine Research Center vaccine candidate in which envelope genes expressing Env from clades A, B, and C and Nef gene from clade B is added.